Targeting FEN1 to improve cancer treatment
FEN1 Endonuclease as a Synthetic Lethal Target for Cancer Therapy
This study is looking at how a specific protein called FEN1 can help improve cancer treatments for people with inherited breast and ovarian cancers caused by BRCA1 and BRCA2 mutations, with the goal of finding new ways to target and kill cancer cells more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10884209 on NIH RePORTER |
What this research studies
This research investigates the role of the FEN1 endonuclease in cancer therapy, particularly for patients with inherited breast and ovarian cancers linked to BRCA1 and BRCA2 mutations. By understanding how FEN1 interacts with other genes involved in genome stability, the research aims to develop new therapeutic strategies that exploit these interactions to selectively kill cancer cells. The approach involves using genetic studies and model systems to identify potential treatment targets that could enhance the effectiveness of existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with hereditary breast or ovarian cancers associated with BRCA1 or BRCA2 mutations.
Not a fit: Patients without BRCA1 or BRCA2 mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for patients with specific genetic mutations.
How similar studies have performed: Previous research has shown success in targeting synthetic lethal interactions in cancer therapy, particularly with PARP inhibitors for BRCA-related cancers.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Kolodner, Richard D — University of California, San Diego
- Study coordinator: Kolodner, Richard D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.